ClinicalTrials.gg
CompletedNCT00322491Updated Mar 13, 2014Results posted

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

A Phase 2 interventional study of G-CSF Plus Plerixafor in Lymphoma, Non-Hodgkin and Multiple Myeloma, sponsored by Genzyme, a Sanofi Company. Completed at 8 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Lymphoma, Non-Hodgkin.

Enrollment
8th of 19
49 · median 36
Started
2004
with 4 others
Phase 2
15 of 19
1 open now
Registered
3rd of 19
by date
Lead sponsor
8 of 19
Genzyme, a Sanofi Company

Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, this one is the 8th largest by enrollment, is one of 5 that started in 2004, is one of 15 in phase 2, and was the 3rd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Efficacy outcomes include evaluation of fold increase in circulating CD34+ cells from just before the first plerixafor injection to 10-11 hours post plerixafor (just before apheresis) and assessment of successful polymorphonuclear leukocyte (PMN) engraftment after transplantation. Data from this protocol will assist in the determination of the dosing schedule for future studies.

Read the detailed description

Participants with NHL and MM who have undergone prior cyto-reductive chemotherapy, are to be autologously transplanted, and meet the inclusion/exclusion criteria are eligible to enter the study. The only change to the standard of care is the addition of plerixafor to a granulocyte colony-stimulating factor (G-CSF) mobilization regimen on the day prior to apheresis. Participants will undergo mobilization with G-CSF (10 mcg/kg each day) and will receive plerixafor (240 mcg/kg) in the evening prior to apheresis. Participants will undergo apheresis for up to 5 consecutive days in order to collect the target number of CD34+ stem cells (≥ 5*10\^6 CD34+ cells/kg for either single or tandem transplant). After apheresis, all participants will be treated with high-dose chemotherapy in preparation for transplantation. Participants will be transplanted with cells obtained from the G-CSF and plerixafor mobilization regimen. The increase in CD34+ cells in the peripheral blood from the time of the plerixafor dose to just prior to apheresis and the number of CD34+ cells in the apheresis product will be measured. The number of apheresis sessions required to obtain ≥ 5*10\^6 CD34+ cells will also be measured. Success of the transplantation(s) will be evaluated by the time to engraftment of polymorphonuclear leukocytes (PMN) and platelets (PLT). Participants will be followed for durability of their transplant for 12 months following transplantation.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma

Keywords

  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • Stem cell mobilization
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of non-Hodgkin's lymphoma (NHL) or multiple myoloma (MM) eligible for transplantation
  • No more than 3 prior regimens of chemotherapy
  • More than 4 weeks since last cycle of chemotherapy. Patient recovered from all acute toxic effects of prior chemotherapy.
  • (ECOG) performance status of 0 or 1
  • White blood cell (WBC) count >3.0*10\^9/L
  • Absolute polymorphonuclear cells (PMN) count >1.5*10\^9/L
  • (PLT) count >100*10\^9/L
  • Serum creatinine \<=2.2 mg/dL
  • Serum glutamic oxaloacetic transaminase (), serum glutamic pyruvic transaminase (SGPT) and total \<2 x (ULN)
  • Left ventricle >45% by normal echocardiogram or multiple-gated acquisition (MUGA) scan
  • Forced expiratory volume of the lung in the first second () >60% of predicted or diffusing capacity of the lung for carbon monoxide (DLCO) >45% of predicted
  • Negative for (HIV) type 1
  • Women of child bearing potential agreed to use an approved form of .

Exclusion criteria

Exclusion Criteria:

  • Patients who have failed previous collections
  • or carcinomatous meningitis
  • History of ventricular arrhythmias
  • A co-morbid condition which, in the view of the investigator, renders the patient at high risk for treatment complications
  • A residual acute medical condition resulting from prior chemotherapy
  • Acute infection
  • Fever (temp >38°C/100.4°F)
  • Patients whose actual body weight exceeds 175% of their ideal body weight
  • Patients who previously received experimental therapy within 4 weeks of enrolling in this study or who are currently enrolled in another experimental study during the mobilization period
  • Positive pregnancy test in female patients
  • Lactating females
  • Patients of unwilling to implement adequate .
  • Patients who have deterioration of their clinical status or laboratory parameters between the time of enrolment and transplant (such that they no longer meet entry criteria) may be removed from study at the discretion of the treating physician, principal investigator, or sponsor.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Non-Hodgkin's Lymphoma (NHL)

    Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Drug: G-CSF Plus Plerixafor

  • Experimental
    Multiple Myeloma (MM)

    Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Drug: G-CSF Plus Plerixafor

Interventions

  • DrugG-CSF Plus Plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Also known as: AMD3100, Mozobil

06

What researchers measure

Primary outcomes

  1. Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)

    Number of participants with treatment emergent adverse events (TEAEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy (approximately day 38). AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').

    Time frame: Day 1 to approximately Day 38 (before start of chemotherapy)

Secondary outcomes

  1. Number of Participants Achieving a Two-Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL Following the First Dose of Plerixafor

    The number of participants mobilized with G-CSF + plerixafor injection who have a ≥ 2-fold increase in CD34+ cells. Fold increase was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL) / (pre-plerixafor dosing PB CD34+ cells/µL)

    Time frame: Days 4-5 (first dose of plerixafor to apheresis)

  2. Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

    Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

    Time frame: 2 months

Other outcomes

  1. Median Cumulative Number of CD34+ Cells Collected During Apheresis

    Median cumulative total number of CD34+ cells collected during apheresis.

    Time frame: Days 5-8

  2. Number of Transplants in Which Participants Achieved Platelet (PLT) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

    Participants were monitored for platelet (PLT) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

    Time frame: 2 months

  3. Number of Participants With Durable Engraftment 12 Months After Transplantation

    The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.

    Time frame: Approximately 13 months (12 months post-transplant )

07

Results

Posted Nov 24, 2010

Participant flow

Participant flow — Overall Study
MilestoneNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
Started2326
Completed2124
Not completed22
Withdrew: Adverse event10
Withdrew: Death12

Outcome measures

PrimaryNumber of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)

Number of participants with treatment emergent adverse events (TEAEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy (approximately day 38). AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').

Time frame:
Day 1 to approximately Day 38 (before start of chemotherapy)
Reported as:
Number · participants
Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)
participantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
Participants reporting ≥ 1 Adverse Event232649
AE Severity (Mild)8917
AE Severity (Moderate)527
AE Severity (Severe)101525
AE Relationship to Drug (Not Related)044
AE Relationship to Drug (Probably Not Related)145
AE Relationship to Drug (Possibly Related)12517
AE Relationship to Drug (Probably Related)81119
AE Relationship to Drug (Definitely Related)224
SecondaryNumber of Participants Achieving a Two-Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL Following the First Dose of Plerixafor

The number of participants mobilized with G-CSF + plerixafor injection who have a ≥ 2-fold increase in CD34+ cells. Fold increase was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL) / (pre-plerixafor dosing PB CD34+ cells/µL)

Time frame:
Days 4-5 (first dose of plerixafor to apheresis)
Reported as:
Number · participants
Number of Participants Achieving a Two-Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL Following the First Dose of Plerixafor
participantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
≥ 2-fold Increase201737
< 2-fold Increase3912
Other pre-specifiedMedian Cumulative Number of CD34+ Cells Collected During Apheresis

Median cumulative total number of CD34+ cells collected during apheresis.

Time frame:
Days 5-8
Reported as:
Median · CD34+ cells (*10^6 / kg)
Median Cumulative Number of CD34+ Cells Collected During Apheresis
CD34+ cells (*10^6 / kg)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
Median Cumulative Number of CD34+ Cells Collected During Apheresis5.2 (1.5 to 18.9)11.1 (4.4 to 22.5)5.9 (1.5 to 22.5)
SecondaryNumber of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

Time frame:
2 months
Reported as:
Number · number of transplants
Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant
number of transplantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
≤ Day 12192039
Day 13 to Day 213710
≥ Day 22000
Other pre-specifiedNumber of Transplants in Which Participants Achieved Platelet (PLT) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

Participants were monitored for platelet (PLT) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

Time frame:
2 months
Reported as:
Number · number of transplants
Number of Transplants in Which Participants Achieved Platelet (PLT) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant
number of transplantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
≤ Day 127714
Day 13 to Day 21101828
≥ Day 22516
Other pre-specifiedNumber of Participants With Durable Engraftment 12 Months After Transplantation

The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.

Time frame:
Approximately 13 months (12 months post-transplant )
Reported as:
Number · participants
Number of Participants With Durable Engraftment 12 Months After Transplantation
participantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
Number of Participants With Durable Engraftment 12 Months After Transplantation212243

Adverse events

Collected over First day of G-CSF administration to the day prior to chemotherapy/ablative treatment in preparation of first transplant. This period includes the G-CSF, plerixafor treatment and rest period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-Hodgkin's Lymphoma (NHL)—0/23 (0%)23/23 (100%)
Multiple Myeloma (MM)—1/26 (3.8%)26/26 (100%)
Most frequent serious events
Most frequent serious events
EventNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
Heparin-induced thrombocytopeniaGeneral disorders0/231/26
Most frequent other events
Showing 10 of 108
Most frequent other events
EventNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
DiarrhoeaGastrointestinal disorders13/2310/26
ParaesthesiaNervous system disorders4/2311/26
NauseaGastrointestinal disorders9/238/26
HeadacheNervous system disorders9/234/26
FatigueGeneral disorders7/234/26
Bone painMusculoskeletal and connective tissue disorders7/236/26
Injection site erythemaGeneral disorders6/233/26
Blood alkaline phosphatase increasedInvestigations3/236/26
InsomniaPsychiatric disorders5/236/26
ThrombocytopeniaBlood and lymphatic system disorders5/233/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Mean56.5 ± 8.757.6 ± 8.157.1 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Female91019
Male141630
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Caucasian232346
African-American011
Hispanic/Latino011
Other011
08

Study locations

8 sites
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas, United States
  • UCLA School of Medicine
    Loa Angeles, California, United States
  • Loyola University Medical Center
    Maywood, Illinois, United States
  • University of Iowa
    Iowa City, Iowa, United States
  • University of Minnesota
    Minneapolis, Minnesota, United States
  • Mayo Clinic
    Rochester, Minnesota, United States
  • Roswell Park Cancer Institute
    Buffalo, New York, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania, United States
09

References and documents

Publications

  • Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56. doi: 10.1016/j.bbmt.2008.11.028. PubMed 19167685 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2006
First posted
May 8, 2006
Start
Mar 2004
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Results first posted
Nov 24, 2010
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00322491
Collaborators
AnorMED
First posted
May 8, 2006
Start date
Mar 2004
Primary completion
Jun 2006
Completion
Jun 2006
Results posted
Nov 24, 2010
Last update
Mar 13, 2014

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion